Kancera provides update on successful phase I study and planned phase II study with KAND567 treatment following heart attack


This is a translation of a press release in Swedish published December 29, 2020

Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces today that the company’s new capsule product with KAND567 has been evaluated in a successful phase I study in Finland and thus is now ready for the planned clinical trial in patients with myocardial infarction. Furthermore, Kancera is collaborating with Professor Ioakim Spyridopoulos and the Newcastle upon Tyne Foundation Hospitals NHS Foundation Trust to start a joint Phase II study as soon as possible with KAND567. The aim of the study is to use biomarkers to evaluate KAND567 with respect to safety and cardioprotective effect. Application for a permit for the study is expected to be submitted to the UK Medicines Agency MHRA during the first quarter of 2021.

”Despite the great stress that the ongoing pandemic places on the hospitals, we see good opportunities to start the planned cardiac study with KAND567 during the first half of 2021, which is about two months later than previously planned. The study will be conducted at Freeman Hospital in the UK, which has been ranked as one of the world’s 100 best hospitals. The fact that the start of studies can take place in a reasonable time frame is due to the great commitment and interest that our partner has for KAND567 and its potential in the field of hyperinflammation in heart disease “, says Thomas Olin, CEO of Kancera.

The planned phase II study of treatment with KAND567 following a heart attack will include sixty patients admitted to hospital for myocardial infarction in the anterior wall of the heart chamber. They are treated for three days with KAND567 or a placebo. Evaluation takes place on days 30 and 90 after the first dose based on safety, markers for cardiovascular and renal protection effects, inflammation and general health.

About Kancera AB (publ)
Kancera AB conducts research and drug development within Karolinska Institutet Science Park in Stockholm in order to counteract hyper-inflammation in various disease states and thereby protect vital organs, for example in connection with heart attacks and severe viral infections. The stock is traded on NASDAQ First North Premier. FNCA Sweden AB is the company’s Certified Adviser. FNCA can be reached at info@fnca.se and on 08-528 00 399. Charlotte Edenius, MD PhD, Anders Gabrielsen, MD PhD, Professor Carl-Henrik Heldin and Professor Håkan Mellstedt are all scientific advisors as well as board members of Kancera AB.

For further information, please contact,
Thomas Olin, CEO: +46-735-20 40 41
Kancera AB (publ)
Karolinska Institutet Science Park
Nanna Svartz Väg 4
SE 171 65 Solna

Please visit the company’s website; https://www.kancera.com